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Although most incarcerated individuals with HIV
infection acquire the virus prior to their impris-
onment, the high prevalence of HIV infection
and frequency of unprotected sex in correction-
al facilities suggest that spread of HIV within
prisons also occurs.  However, few studies have
investigated intramural transmission of HIV
infection in the U.S. and most of these, con-
ducted early in the epidemic, reported a low
incidence of HIV infection within prisons.1-3 A
more recent study of 446 incarcerated men in
Rhode Island found no cases of HIV serocon-
version after 694 person-years of in-prison fol-
low-up; in contrast, transmission of hepatitis B
virus and hepatitis C virus were observed.4
The primary challenge to determining the inci-
dence of HIV during incarceration is the
absence of HIV testing data at both the time of
incarceration and release.  Few correctional
systems conduct testing at entry and exit, and
those that do have not published their findings.
More common is the performance of HIV
screening of inmates at the time of their incar-
ceration; among a subset requesting testing or
for whom the test is clinically indicated, an HIV
test is repeated during the incarceration.   
Last month, the Centers for Disease Control
and Prevention (CDC) reported in the Morbidity
and Mortality Weekly Reports (MMWR) the
investigation of 88 male inmates of the Georgia
Department of Corrections who between 1992
and 2005 were found to have acquired HIV dur-
ing their incarceration.5 Those with documented
HIV seroconversion while incarcerated all had
previously been found to be seronegative at
prison entry when they were tested as part of
Georgia's policy of mandatory HIV testing of
new prison inmates.  Almost half (47%) were
discovered to be HIV-infected during a program
started in 2003 offering voluntary HIV testing
annually to all inmates, while the remaining
inmates were found to be HIV-positive after
requesting to be HIV tested or receiving the test
as part of their clinical care.  This annual HIV
testing program ended in 2005.  Of the 88
inmates who seroconverted, the median age at
time of the detection of HIV was 32 years
(range: 21-58 years); 67% were black and 33%
were white.
To examine risk factors associated with HIV
infection during incarceration, the CDC conduct-
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ed two case-control studies to compare the
men who acquired HIV in prison with
inmates who remained HIV-uninfected.  In
the first, infected cases were compared to
a random selection of unmatched, uninfect-
ed controls who resided in one of the seven
facilities where most of the cases were
believed to have become HIV-infected.  In
the second study, cases were contrasted to
control subjects selected from the 31 state
prison facilities in Georgia where case
inmates were housed and matched by sen-
tence length and time already served.
Multivariable analysis of the unmatched
study found HIV seroconversion to be sta-
tistically significantly associated with self-
reported male-male sex in prison, older
age, having served >5 years of the current
sentence, and having a body mass index
(BMI) of <25.4 kg/m2 on entry into prison.
In a similar analysis of the matched study,
self-reported sex with men in prison,
receiving a prison tattoo, a BMI of <25.4
kg/m2 on entry into prison, and black race
were significantly associated with serocon-
version. (see Table 1) Notably, 32% of the
cases and 6% of the matched controls
reported sex with a male staff member and
22% of cases and 9% of these controls
stated they had sex with female prison
staff.  Of 43 inmates (34 cases and nine
controls) who reported engaging in consen-
sual sex, 13 (30%) said they used condoms
or other improvised barrier methods includ-
ing rubber gloves and plastic wrap.
The association between HIV in-prison
seroconversion and low BMI may be due to
the sexual victimization of smaller men;
however, sex was overwhelmingly reported
by participants to be consensual with only
9% of cases and 1% of controls reporting
being a victim of rape during incarceration.  
In an accompanying editorial, the CDC rec-
ommended that HIV prevention efforts in
prisons address male-male sex, injection
drug use and tattooing, and that inmate-led
interventions may be particularly effective.
Reflecting the report by participants of sex-
ual contact between staff and inmates, it
was suggested that HIV education not be
limited to only inmates.  In addition, it was
recommended that HIV testing at prison
entry and exit should be conducted and
voluntary testing offered regularly during
the incarceration.  The CDC was less direct
regarding condom distribution in correc-
tional settings.  Noting that condoms are
provided to some inmates in state prisons
in Mississippi and Vermont and jails in Los
Angeles, New York, Philadelphia, San
Francisco, and the District of Columbia, the
editorial recommended that these pro-
grams be evaluated and that departments
of corrections "should assess relevant state
laws, policies, and circumstances to deter-
mine the feasibility and benefits and risks of
implementing such programs."
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See the Spotlight for two different per-
spectives on the results of the CDC
investigation
Dear Correctional Colleagues, 
Last month the CDC's Morbidity and Mortality Monthly Report
(MMWR) included a report on the documented serocoversion of
88 men incarcerated within the Georgia Department of
Corrections.  The report and an accompanying editorial by CDC
authors raise important concerns regarding the spread of HIV
within correctional settings and the appropriate measures to pre-
vent such transmission.  Since the release of the MMWR article,
the IDCR board of editors has discussed the implications of the
report and how the newsletter should respond.  Through our con-
versations we have learned that among the members of the
board there are strong yet diverse views on several issues raised
by the article including the magnitude of intramural spread of HIV
infection, who is responsible for preventing HIV transmission in
correctional facilities and what is the role of interventions such as
inmate access to condoms and sterile syringes in correctional
settings.  
Our opinions were most divergent on the issue of condoms.
Some board members feel that the findings reported in the arti-
cle are a wake-up call for greatly enhancing HIV prevention in
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Table 1. Multivariable analysis of characteristics and risk behaviors among
inmates with HIV seroconversion in prison compared to matched controls
*Of the 88 HIV seroconverters, 11 were released from prison and two died before the
start of the case-control study.  Of the 75 remaining seroconverting inmates, 68 were
enrolled in the case controlled studies. 
Modified from: CDC. HIV Transmission Among Male Inmates in a State Prison System --
- Georgia, 1992--2005. MMWR Morb Mortal Wkly Rep. 2006;55(15):421-6.
Characteristic/Behavior Cases
(n=68)*
No
%
Controls
(n=68)
No
%
Adjusted
Odds
Ratio
95% CI p value
Male-male sex in prison
Received prison tattoo
BMI <24.5 kg/m
2
Black race
45
40
51
45
66
59
75
66
9
28
23
40
13
41
34
59
10.1
13.7
3.8
3.7
3.0 - 54.9
1.5 - 390.6
1.2 - 15.2
1.1 - 16.7
<0.01
0.01
0.02
0.03
Multivariable Analysis
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prisons and that a centerpiece of these efforts should be the distribution of condoms - an HIV
and STD prevention tool that has been repeatedly demonstrated to be effective in a variety of
settings.  Arguments regarding any potential danger of condoms in the hands of prison inmates,
these members felt, are short on data and long on misplaced moralizing.  Other members
counter that much is currently being done to prevent HIV transmission in prisons, that such trans-
mission events are relatively rare and that future efforts to reduce intramural spread of HIV
should focus on abstinence and perhaps being faithful (the A and B of the ABC prevention para-
digm) rather than C, condoms.  Several also caution that the CDC report was based on self-
reported data from inmates and although these interviews were conducted using computer
assisted techniques designed to reduce bias, the information collected remain self-reported and
unsubstantiated.   To these board members, the extremely troublesome reports of sex with prison
staff by inmates in Georgia need to be taken with a heap of salt.  However, we all agree that such
documented contact between prison staff and inmates should be considered sexual abuse and
punished accordingly. 
There was greater consensus on the value of HIV screening in prisons with most agreeing that
HIV testing is an important component of HIV prevention in this setting.  That half of the HIV sero-
conversions in the Georgia Department of Corrections were detected via an annual voluntary HIV
testing program was an important finding of the MMWR report.  States have individual approach-
es to HIV screening of prison inmates as described in detail in the April IDCR.  Yet, the CDC is
recommending all state prison systems expand HIV testing to include voluntary screening during
incarceration. 
To get their perspectives on the MMWR report we asked Joseph Paris, the former medical direc-
tor of the Georgia Department of Corrections (who is also an IDCR board member), and
Madeleine LaMarre, an author of the report, to provide their views on the implications of the
results.  The aim of our coverage is to permit IDCR readers a unique opportunity to become
familiar not only with the details of the MMWR report but also the perspectives of these key indi-
viduals when considering their own response to the report.  I suspect that like our board our read-
ership will also have a range of responses to the MMWR findings.  We continue to encourage
you to write us with your views.  Selected letters to the editor will be published on our new "read-
er response" page online at http://www.IDCRonline.org.  
Lastly, CME questions regarding the MMWR report will address the main points that are covered
in a brief summary article, including the type of study that was performed, the main findings of
the study, and the recommendations that were provided by the accompanying editorial.
David Alain Wohl, MD
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The author is the former Statewide Clinical
Services Manager of the Georgia Department
of Corrections. She is one of the co-authors of
the MMWR report. This editorial represents her
personal views and not that of any governmen-
tal agency.
Since the publication of the MMWR, some
correctional health professionals and news
media concluded that the study showed
that the incidence of HIV infections in the
Georgia Department of Corrections (GDC)
is low.  Specifically, Dr. Joseph Paris mis-
characterizes the study as a disease inci-
dence study and then draws the conclusion
that HIV incidence is low in GDC prisons.  It
is important to clarify that data collected did
not permit calculation of HIV incidence
rates, since prior to 2003, inmates were
tested only upon arrival into GDC and not
tested again, unless they showed signs of
illness or requested to be tested. During
this time, thousands of inmates came into
the system and departed without having
another HIV test. If new infections
occurred, they were unlikely to have been
identified. Moreover, for those HIV infec-
tions that were detected, GDC did not have
a centralized surveillance system to report
and track new infections until 2003. Thus, it
is not possible to draw any conclusion
regarding the incidence of HIV infections in
GDC from this report.  
Since 1988, Georgia state law has required
mandatory HIV testing of all newly admitted
inmates. No further periodic testing was
conducted until 2003 when voluntary, annu-
al HIV testing was implemented in GDC.
The rationale for this testing policy was pro-
vided when GDC mortality reviews identi-
fied several cases of inmates who died of
HIV-related disease and were diagnosed
at, or shortly before, death. In an effort to
reduce HIV-related morbidity and mortality,
GDC implemented annual testing to enable
early identification, counseling and treat-
ment of newly infected inmates. 
This testing policy and surveillance pro-
gram resulted in the identification of 88
inmates who seroconverted while incarcer-
ated. GDC recognized that these inmates
did not represent the sum of all inmates
who acquired HIV infection while incarcer-
ated, but it was this group of known sero-
converters who served as the basis for the
case-control study. The 88 seroconversions
are not an insignificant number when one
considers both the cost of medical treat-
ment and potential sources of transmission
to others. It also should be noted that 41
(47%) of the 88 HIV seroconverters in this
study were identified during the two years
in which annual testing was offered.
Without periodic testing, many of these
inmates would not have been diagnosed in
a timely manner and provided access to
medical care. In October of 2005, after the
conclusion of this study, of 856 male
inmates known to be HIV-positive in GDC,
76 (9%) had been infected during incarcer-
ation. Due to population turnover, this 76
included inmates who were part of the
study as well as some who were diagnosed
after the study began. It is noteworthy that
almost ten percent of these prevalent HIV-
infected male inmates acquired their infec-
tion during incarceration. 
In the MMWR the CDC concludes that
Joseph Paris, MD
The author is former Medical Director at the
Georgia Department of Corrections
The recent MMWR study regarding the
Georgia Department of Corrections (GDC)
is in many ways a first and brings about
much food for thought. Inevitably, a study of
this breadth and complexity may lead to
misinterpretations and sensationalism. I
was the GDC Medical Director during the
last decade of the study period and I
believe I have some understanding of the
underlying issues. 
As physicians and human beings, we
should feel the pain of each intramural
seroconversion, which is a very real, per-
sonal tragedy. Yet, in my opinion, the
MMWR paper should have highlighted the
relatively low number of intramural conver-
sions. The study period was 17 years. If
one assumes the rate of conversions was
approximately even throughout, there were
about 5.1 intramural HIV conversions per
year. The GDC today has about 50,000
inmates, but this is a static number which
does not reflect the fact that, in any given
year, there is a turnover of approximately
25,000 inmates. Therefore, by each year's
end, the GDC had provided medical care
and HIV testing to some 75,000 persons (if
every inmate were to accept annual volun-
tary re-testing; in practice, about 10% do
not). Further, because of the nearly 50%
yearly turnover, the GDC housed perhaps
6,000 or more HIV-infected individuals.
Additionally, it is not known how many
inmates may have been infected just prior
to incarceration (i.e., during the window
period).
With so many infected persons passing
through the GDC, no cohorting of HIV-pos-
itive inmates, and a large number of sus-
ceptible inmates, why was intramural trans-
mission so low?   
I believe that the media will likely misinter-
pret the MMWR data on the route of infec-
tion for the intramural conversions. The fig-
ures given for prisoner risk activities like
sex, injection drug use, and other behaviors
were self-reported, with all the implications
on their validity. Also, the number of sero-
converted and matched non-seroconverted
inmates interviewed was very small. Again,
if these figures for risk behaviors are cor-
rect, why was the yearly rate of intramural
seroconversions so small?
The paper discusses the pros and cons of
cohorting to lower the already very low rate
of intramural conversions. But, cohorting is
not a real option. To cohort or segregate so
as to ensure the existence of "guaranteed
HIV-free prisons," one would have to con-
sider the very real possibility that in such
perceived "HIV-free prisons" inmates may
forego precautions and embark in risky
behavior because of the assumed safety. It
is quite possible that in such facilities intro-
duction of HIV by a single case within the
testing window, or by infected staff (a risk
acknowledged in the paper's editorial note),
may spread the virus rapidly and infect
large numbers of inmates. In order to guar-
antee that a prison is "HIV-free," one would
have to test at intake--whether tested previ-
ously at another prison or not--re-test at the
end of the window (e.g., at 6 months) and
periodically re-test all inmates, perhaps as
frequently as every 6 months. I posit that it
would be very difficult and expensive to
maintain a "guaranteed HIV-free prison."
Whether the authors considered the trans-
mission rates to be high or low is not
apparent from the paper. Further, the paper
did not comment on the decision by GDC in
2005 to stop annual, voluntary, universal
HIV re-testing. It seems that studies like
this one, so very enlightening despite its
limitations, will not be repeated in Georgia
for some time.
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DEPARTMENT OF CORRECTIONS FOR HIV PREVENTION IN PRISONS?
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periodic HIV testing was useful and recom-
mends that HIV screening be provided upon
entry into prison, before release, and that
voluntary HIV testing be offered periodically
during incarceration. The CDC also recom-
mends that correctional agencies assess
the feasibility of implementing risk-reduction
measures such as condom distribution to
prevent disease transmission.
Unfortunately, in June 2005, the medical
leadership of the GDC Office of Health
Services discontinued voluntary annual HIV
antibody testing. The result is that newly
HIV-infected persons are unlikely to be
identified, counseled and offered treatment.
Further, it is likely that some inmates' infec-
tions will not be identified until they are hos-
pitalized or have died. Other inmates will be
released into communities and may
unknowingly infect others. Lastly, no further
data will be collected that could be used to
calculate disease incidence or assess the
effectiveness of HIV and other sexually
transmitted and blood-borne disease pre-
vention strategies. This represents a
missed opportunity to protect the health of
inmates and the community, and to con-
tribute to the body of knowledge regarding
communicable disease prevention in pris-
ons and jails. Hopefully, this testing policy
will be reconsidered by GDC leadership. It
is further hoped that correctional agencies
across the country will implement testing
policies consistent with CDC recommenda-
tions and will develop comprehensive pre-
vention strategies that include:  
? Ongoing inmate and staff education
regarding prevention of HIV and other
sexually transmitted and blood-borne
infections;
? HIV counseling and testing;
? Hepatitis B vaccination; and
? Access to risk-reduction measures (e.g.
condoms, and bleach to disinfect drug
injection and tattooing equipment.) 
The challenges of delivering health care in
correctional facilities often results in insuffi-
cient attention to disease prevention.
Studies such as this are a call to action to
correctional health leaders to strengthen
disease prevention efforts.
SPOTLIGHT...
(continued from page 4)
Evaluation and Treatment of Possible Non-Occupational HIV Exposures
IDCR-O-GRAM
Substantial
exposure risk
Negligible
exposure risk
< 72 Hours
since exposure
> 72 Hours
since exposure
Source patient
known to be 
HIV positive
Source patient
of unknown 
HIV status
nPEP
recommended
nPEP not
recommended
Case-by-case
determination
Substantial Risk for HIV Exposure
Exposure of
vagina, rectum, eye, mouth,
or other mucous membrane,
nonintact skin, or percutaneous contact
With
blood, semen, vaginal secretions, rectal
secretions, breast milk, or any body fluid
that is visably contaminated with blood
When
the source is known to be HIV-infected
Negligble Risk for HIV Exposure
Exposure of
vagina, rectum, eye, mouth,
or other mucous membrane,
intact or nonintact skin, or 
percutaneous contact
With
urine, nasal secretions, saliva, sweat,
or tears if not visably contaminated 
with blood
Regardless
of the known or suspected HIV status
of the source
Source: CDC. Management of Possible Sexual, Infection-Drug-Use, or Other Nonoccupational Exposure to HIV, Including Considerations Related to
Antiretroviral Therapy - January 21, 2005
http://aidsinfo.nih.gov/ContentFiles/NonOccupationalExposureGL.pdf
Understanding Our Patients:
HIV and Women in
Corrections
June 16, 2006
Moody Gardens Resort and
Conference Center
Galveston, Texas
For registration information, 
e-mail: vikorsch@utmb.edu
International Prisoner
Health: Achieving
International Standards in
Prison Health Care
June 19-20, 2006
Tallinn, Estonia
http://www.tandfevents.com/pri
sonerhealth
African Women in the
Diaspora Conference:
Empowering African
Women, Ensuring Africa's
Future 
June 22, 2006
Minneapolis, MN
http://www.mawanet.org/html/c
onference.htm
American Correctional
Association Conference
August 12-17, 2006
Charlotte, NC
http://www.aca.org/confer-
ences/summer06/
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Directly Administered Antiretroviral Therapy
(DAART) News
Amy Wohl et al.1 enrolled 250 HIV-infected individuals
from three Los Angeles HIV clinics into a randomized,
controlled six-month trial that evaluated whether DAART
or intensive adherence case management (IACM) had
beneficial effects on patients' CD4+ cell counts and HIV
viral load, as compared to the standard of care (SOC).
Participants were both treatment-naïve (46%) (treatment
<6 months) and treatment-experienced (54%); 57%
spoke Spanish only and 73% were unemployed. The 82
persons assigned to the DAART arm received daily
deliveries of their medications and took one dose,
Monday through Friday, in the presence of a bilingual
community worker. The 84 participants receiving IACM
were instructed to take their medications without super-
vision and met on a weekly basis with a case manager.
The 84 persons in the control (SOC) group were told to
take their medications without supervision, and met with
their clinics' case managers on a quarterly basis. Over
the course of six months, overall retention was 78%.
More patients in the DAART arm (18%), as compared to
the SOC arm (4%), dropped out of the study early; 40%
these DAART participants cited that they exited the
study because it required too much time or did not fit into
their schedules. 
At six months, there was no significant difference
between the three study arms in terms of the percentage
of patients with an undetectable viral load (defined as
<400 copies/mL), nor in terms of median CD4+ cell
count, change of CD4+ cell count from baseline, or self-
reported adherence to HAART. As a potential explana-
tion, the authors propose that the adherence support
provided by each of the three clinics was sufficient. They
conclude that DAART may be most beneficial to patients
with a history of adherence problems.
A second study addressed the impact of DAART among
a population that traditionally has problems with adher-
ence to HAART: injection drug users (IDU). Lucas et al.2
compared medication adherence, HIV viral load, and
CD4+ cell count among HIV-infected IDU attending
three Baltimore methadone clinics and receiving DAART
versus three groups of HIV-infected patients of the
Johns Hopkins Clinic self-administering their HAART:
patients with a history of IDU receiving methadone and
HAART (n=75), patients with a history of IDU but not
receiving methadone while on HAART (n=244) and
patients with no IDU history and on HAART (n=490).
The 82 participants in the DAART arm received one
dose of HAART each morning that they went to their
methadone clinic. The 809 participants in the three com-
parison groups self-administered their HAART regimens. 
At 12 months, 56% of DAART participants had an unde-
tectable viral load (<400 copies/mL); this proportion was
significantly higher than the percentage in each of the
three comparison groups (range 32-44%). DAART par-
ticipants also experienced a significantly higher increase
in median CD4+ cell count as compared to the compar-
ison group participants. The authors conclude that
methadone clinic-based DAART can potentially provide
significant clinical benefit for HIV-infected injection drug
users.
An editorial by Flanigan and Mitty3 points us in the direc-
tion of future research: "…will community-based DAART
provide a benefit to active substance users?"  They pro-
pose that DAART may be most feasibly instituted as a
short-term intervention for substance users, given the
tendency of this population to cycle through correctional
systems and to frequently change residences.
1. Wohl AR, Garland WH, Valencia R, Squires K, Witt MD,
Kovacs A, Larsen R, Hader S, Anthony MN, Weidle PJ. A ran-
domized trial of directly administered antiretroviral therapy and
adherence case management intervention. Clin Infect Dis.
2006;42(11):1619-27.
2. Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME,
Moore RD. Directly Administered Antiretroviral Therapy in
Methadone Clinics Is Associated with Improved HIV Treatment
Outcomes, Compared with Outcomes among Concurrent
Comparison Groups. Clin Infect Dis. 2006;42(11):1628-35.
3. Flanigan TP, Mitty JA. The Good, the Bad, and the Ugly:
Providing Highly Active Antiretroviral Therapy When It Is Most
Difficult. Clin Infect Dis. 2006;42(11):1636-38.
Prison-Based HIV Prevention Intervention
Analysis
Bryan et al.4 assessed the efficacy of a six week, prison-
based HIV prevention program and explored how
race/ethnicity impacted prisoners' acceptance of the
intervention. One hundred and ninety-six inmates (mean
age 30 years, range 17-60; 90% male; 40% African-
American, 28% Hispanic, 22% Caucasian) in
Northeastern prisons voluntarily enrolled. According to
pre-intervention questionnaire responses, 5% of partici-
pants were HIV-infected and 21% had injected drugs; of
these, 83% had shared needles. The intervention uti-
lized the teaching methods of the Connecticut
Department of Corrections' Beyond Fear program, which
educates inmates about HIV transmission, prevention
and testing and aims to improve self-efficacy for HIV pre-
vention while encouraging inmates to become peer edu-
cators. 
Following a post-intervention assessment, the authors
concluded that the intervention was most successful at
influencing beliefs and behaviors regarding peer educa-
tion, less successful at influencing ideas about condom
use, and least successful regarding needle-sharing
behaviors--though it is noteworthy that participants who
had shared needles did indicate a greater intent to not
share needles. Female participants demonstrated a
greater knowledge gain following the intervention as
compared to men, as did younger participants with
respect to older ones. Caucasian and African-American
participants showed an increase regarding to self-effica-
cy related to condom use, while Hispanic participants
showed a decrease; Caucasians showed the highest
increases related to intentions to use condoms. The
authors suggest that future HIV prevention interventions
may benefit from a higher degree of cultural relevance,
and the Beyond Fear program has been revised in
response to Hispanic inmates' suggestions.
4. Bryan A, Robbins RN, Ruiz MS, O'Neill D. Effectiveness of an
HIV Prevention Intervention in Prison Among African Americans,
Hispanics, and Caucasians. Health Education & Behavior.
2006;33(2):154-177.
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Tenofovir’s Genital Tract Successes
Several studies point to the potential use of tenofovir as
a pre-exposure prophylaxis to prevent HIV infection.
Vourvahis et al.5 conducted the first study to measure
tenofovir extra- and intra-cellular concentrations in
men's and women's genital tracts from Day 1 to a
steady-state. Twenty-two HIV-infected individuals partic-
ipated; at enrollment, nine were not taking antiretrovirals
(ARVs) and 13 were on a stable ARV plan. The nine
individuals were treated with tenofovir monotherapy for
14 days; the 13 participants had tenofovir added to their
regimen for greater than 20 days. 
Tenofovir levels were significantly greater in the genital
tract than in the blood in both men and women at Day 1
and at steady-state levels. In the genital tract, high con-
centrations of tenofovir were found both extra- and intra-
cellularly in men, and extra-cellularly in women.
Additionally, tenofovir monotherapy significantly
reduced HIV-1 RNA both in the blood and genital tract
over a period of 14 days in both men and women.
Clinical trials are underway in the U.S. and the develop-
ing world to examine the safety and effectiveness of
both tenofovir and truvada as pre-exposure prophylaxis.
In the first Phase I clinical trial to study an ARV as a
potential vaginal microbicide, Mayer et al.
6
showed vagi-
nal application of a tenofovir-containing gel to be safely
tolerated by HIV-infected and uninfected women.
Eighty-four women (24 HIV-infected, 60 HIV-uninfected;
24 sexually active, 60 abstinent; 45% African American,
35% Caucasian, 19% Latina) were assigned to use var-
ied doses of the study product for 14 days. A 1% teno-
fovir gel used twice daily was as well tolerated as once-
or twice-daily 0.3% regimens used by the 48 HIV-unin-
fected sexually abstinent women, establishing the high-
est practical dose and frequency. The authors stated,
"Though 92% of the women reported at least one
adverse event, the majority were mild (87%) and
involved the genitourinary tract (70%), and specific
adverse event patterns were not associated with gel
concentration, sexual activity, or HIV status." Serum
tenofovir levels were measured in 25 women; 14 (56%)
revealed low but detectable serum levels. Among the
HIV-infected women, no new reverse transcriptase
resistance mutations were detected in HIV RNA after 14
days of tenofovir gel use, and none had detectable cer-
vicovaginal HIV RNA at Day 14. Of the 81 women (HIV-
infected and un-infected) who completed the 2 week
course, 76 (94%) fully adhered to the study and 94%
said that they would definitely or probably use the gel if
it were available and they wanted to prevent HIV trans-
mission; 81% of their male partners agreed that they
would use the gel under similar circumstances. Given
their results, the researchers support the expansion of
safety and effectiveness testing and development of
effective microbicide delivery devices.
5. Vourvahis M, Tappouni H, Patterson K, Chen Y, Rezk NL,
Fiscus S, Kearney BP, Rooney JF, Cohen M, Kashuba ADM. A
Pharmacologic Basis for the Use of Tenofovir in Pre- and Post-
Exposure Prophylaxis: Intra and Extracellular Genital Tract
Pharmacokinetics and Pharmacodynamics from First Dose to
Steady State in HIV-1 Infected Men and Women. Presented at
the 13th CROI, Denver, Colorado. February 5-8, 2006.
6. Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J,
Kwiecien A, Masse B, Eshleman SH, Hendrix C, Morrow K,
Rooney JF, Soto-Torres L; HPTN 050 Protocol Team. Safety and
tolerability of tenofovir vaginal gel in abstinent and sexually
active HIV-infected and uninfected women. AIDS.
2006;20(4):543-551.
Man charged for unprotected sex with women
in Wisconsin
According to a report in the Janesville Gazette,
7
in 1996,
a Wisconsin man was sentenced to six years imprison-
ment for having unprotected sex without disclosing his
HIV infection to three partners. Ten years later, he has
been accused of repeating that behavior. According to a
search warrant affidavit, the man told a woman he had
met in a bar that she "did not need to worry about" hav-
ing unprotected sex with him. The woman's friends rec-
ognized the defendant from coverage of the 1996 case,
yet when she asked him about his identity he denied
being that person. The woman looked up the case at her
public library, and eventually the man admitted his iden-
tity and HIV-status to her. He qualified his admission by
stating that his HIV infection was "under control" and
that his "blood levels were not at a contagious level,"
according to court records.
In 1996, the man pleaded no-contest to three felony
charges of reckless endangerment; he is now expected
to plead no-contest to second-degree reckless endan-
germent, using his prior time served in prison to his
favor. 
7. The Janesville Gazette. Available at
http://www.gazetteextra.com/hivcharges040706.asp. April 7,
2006.
XVI International AIDS
Conference
August 13-18, 2006
Toronto, Canada
http://www.aids2006.org/
11th World Conference on
Public Health
August 21-25, 2006
Rio de Janeiro, Brazil
http://www.saudecoleti-
va2006.com.br/ingles/presen-
tation.php
Correctional Medicine
Institute's 2006 Intensive
Review in Correctional
Medicine
September 15-17, 2006
Baltimore, MD
http://www.cmi2006.org/
American Public Health
Association 134th Annual
Meeting and Exposition
November 4-8,2006
Boston, MA
http://www.apha.org/meetings/
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1.  Which of the following is TRUE regarding a recent study of 
the incidence of HIV, hepatitis B virus (HBV) and hepatitis C
virus (HCV) among prisoners in Rhode Island
A. There were no cases of new HBV or HCV infection 
B. There were no cases of HIV seroconversion detected 
during the study period
C. All prisoners acquiring HIV in prison also had HBV co-
infection
D. Due to wide spread HBV vaccination, there were no 
cases of HBV but HCV seroconversion was observed
E. None of the above
2.  In the MMWR report on HIV transmission in the Georgia 
Department of Corrections each of the following was found to 
be associated with HIV seroconversion in prison EXCEPT:
A. Male-male sex
B. Obtaining a tattoo in prison
C. Low body mass index
D. Being incarcerated for a drug-related offense
3.  To assess risk factors associated with acquiring HIV infection 
in the Georgia prison system the CDC conducted which type 
of study/studies:
A. A case control study
B. A randomized controlled trial
C. A prospective cohort study
D. A and B
E. A and C
4.  In an accompanying editorial to the MMWR report, CDC 
authors recommended which of the following: 
A. Prisons should consider HIV prevention programs that 
incorporate peer-led interventions
B. Prison staff should be trained in HIV prevention mea
sures
C. HIV testing at prison entry and exit should be conducted 
and testing offered regularly during the incarceration 
D. All of the above
5.   According to the MMWR report, of the 88 inmates document
ed to have experienced HIV seroconversion while in prison all 
of these infections were detected from 2003 to 2005 when 
HIV testing was offered to inmates annually (TRUE or False)?
A. True
B. False
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